RENBP and autoimmune thrombocytopenic purpura: And our study found that the therapeutic activity of EJSW against ITP might be related to downregulating inflammatory factors and reducing vascular endothelial injury and regulating relevant pathways (VEGF signalling, AGE- RAGE signalling, and complement and coagulation cascade signalling pathways).